According to filings with the U.S. Securities and Exchange Commission, Shape Memory Medical is raising up to $10 Million in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Shape Memory Medical
Shape Memory Medical is a California-based global medical device company focused on developing innovative therapeutic solutions using proprietary shape memory polymer (smart polymer) technology for endovascular applications. The company reshapes clinical success by engineering smart polymer-based embolization devices that stimulate the immune response, promote healing, and support the growth of healthy new tissue as the material slowly bioabsorbs without chronic inflammation. Shape Memory Medical is the first medical device company to introduce an FDA-cleared medical device utilizing shape memory polymer (SMP) technology to a vascular market, and it continues to build a cross-specialty portfolio to meet the demands of peripheral vascular, cardiovascular, neurovascular, and emerging aortic procedures. Its smart polymer devices are designed to conform dynamically to patient anatomy, provide stable occlusion and fill without unnecessary force, and elevate device performance by redefining procedural possibilities beyond traditional embolization. The companys technology originated from research at Texas A&M University and Lawrence Livermore National Laboratory funded by the National Institute of Biomedical Imaging and Bioengineering, and Shape Memory Medical was recognized as one of the 40 Best University Startups 2017 by the National Council of Entrepreneurial Tech Transfer.

To learn more, visit https://www.shapemem.com/
LinkedIn: https://www.linkedin.com/company/shape-memory-therapeutics-inc.

Contact:
Edward Ruppel, Chief Executive Officer

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.